Enrichment strategy and initial characterization of heterodimers enriched from a co-formulated cocktail of therapeutic antibodies against SARS-COV-2

References

• Kim J, Kim YJ, Cao M, Mel ND, Miller K, Bee JS, Wang J, Wang X, Albarghouthi M. Analytical characterization of coformulated antibodies as combination therapy. mAbs. 2020;12(1):1738691. doi:10.1080/19420862.2020.1738691.
   PubMed Web of Science ®Google Scholar
• Chauhan VM, Zhang H, Dalby PA, Aylott JW. Advancements in the co-formulation of biologic therapeutics. J Control Release. 2020;327:397–12. doi:10.1016/j.jconrel.2020.08.013
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Lagassé D, Pedras-Vasconcelos J, Golding B, Rosenberg AS. Evaluating and mitigating the immunogenicity of therapeutic proteins. Trends Biotechnol. 2018;36(10):1068–84. doi:10.1016/j.tibtech.2018.05.008
   PubMed Web of Science ®Google Scholar
• Yan Y, Xing T, Liu AP, Zhang Z, Wang S, Li N. Post-column denaturation-assisted native size-exclusion chromatography–mass spectrometry for rapid and in-depth characterization of high molecular weight variants in therapeutic monoclonal antibodies. J Am Soc Mass Spectrom. 2021;32(12):2885–94. doi:10.1021/jasms.1c00289
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95–106. doi:10.1038/nrc2051
   PubMed Web of Science ®Google Scholar
• Krieg D, Winter G, Svilenov HL. It is never too late for a cocktail - development and analytical characterization of fixed-dose antibody combinations. J Pharm Sci. 2022;111(8):2149–57. doi:10.1016/j.xphs.2022.05.014
   PubMed Web of Science ®Google Scholar
• Baral PK, Yin J, James MNG. Treatment and prevention strategies for the COVID-19 pandemic: a review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol. 2021;186:490–500. doi:10.1016/j.ijbiomac.2021.07.013
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274–78. doi:10.1126/science.abc2241
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;384(3):238–51. doi:10.1056/NEJMoa2035002
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–14. doi:10.1126/science.abd0827
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–18. doi:10.1126/science.abd0831
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi:10.1056/NEJMoa2108163
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu AP, Wang S, Daly TJ, Li N. Ultrasensitive characterization of charge heterogeneity of therapeutic monoclonal antibodies using strong cation exchange chromatography coupled to native mass spectrometry. Anal Chem. 2018;90(21):13013–20. doi:10.1021/acs.analchem.8b03773
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003 Jul 1;31(13):3784–8. doi:10.1093/nar/gkg563. PMID: 12824418; PMCID: PMC168970.
   PubMed Web of Science ®Google Scholar
• Joyce JG, Cook JC, Przysiecki CT, Lehman ED. Chromatographic separation of low-molecular-mass recombinant proteins and peptides on superdex 30 prep grade. J Chromatogr B Biomed Appl. 1994;662(2):325–34. doi:10.1016/0378-4347(94)00206-1
   PubMedGoogle Scholar
• Yan Y, Xing T, Wang S, Daly TJ, Li N. Online coupling of analytical hydrophobic interaction chromatography with native mass spectrometry for the characterization of monoclonal antibodies and related products. J Pharm Biomed Anal. 2020;186:113313. doi:10.1016/j.jpba.2020.113313
   PubMed Web of Science ®Google Scholar
• Pavon JA, Li X, Chico S, Kishnani U, Soundararajan S, Cheung J, Li H, Richardson D, Shameem M, Yang X. Analysis of monoclonal antibody oxidation by simple mixed mode chromatography. J Chromatogr A. 2016;1431:154–65. doi:10.1016/j.chroma.2015.12.068
   PubMed Web of Science ®Google Scholar
• Jiang H, Xu W, Liu R, Gupta B, Kilgore B, Du Z, Yang X. Characterization of bispecific antibody production in cell cultures by unique mixed mode size exclusion chromatography. Anal Chem. 2020;92(13):9312–21. doi:10.1021/acs.analchem.0c01641
   PubMed Web of Science ®Google Scholar
• Yan Y, Xing T, Wang S, Daly TJ, Li N. Coupling mixed-mode size exclusion chromatography with native mass spectrometry for sensitive detection and quantitation of homodimer impurities in bispecific IgG. Anal Chem. 2019;91(17):11417–24. doi:10.1021/acs.analchem.9b02793
   PubMed Web of Science ®Google Scholar
• Knight MJ, Floret L, Patel N, O’Hara J, Rodriguez E. The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity. Mabs-austin. 2022;14(1):2127172. doi:10.1080/19420862.2022.2127172
   PubMed Web of Science ®Google Scholar
• Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol. 2021;2(4):1004–20. doi:10.1039/D1CB00067E
   PubMedGoogle Scholar
• Swanson MD, Rios S, Mittal S, Soder G, Jawa V. Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates. Front Immunol. 2022;13:915412. doi:10.3389/fimmu.2022.915412
   PubMed Web of Science ®Google Scholar
• Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO. et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287(30):25266–79. doi:10.1074/jbc.M111.330902
   PubMed Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, Kiialainen A, Koulov A, Boll B, Weiser T. et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015;32(7):2344–59. doi:10.1007/s11095-015-1627-0
   PubMed Web of Science ®Google Scholar
• Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker MP, Herskovitz J, Goletz TJ, Zhou L. et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PloS One. 2016;11(8):e0159328. doi:10.1371/journal.pone.0159328
   PubMed Web of Science ®Google Scholar
• Yan Y, Xing T, Wang S, Versatile LN. Versatile, sensitive, and robust native LC–MS platform for intact mass analysis of protein drugs. J Am Soc Mass Spectrom. 2020;31(10):2171–79. doi:10.1021/jasms.0c00277
   PubMed Web of Science ®Google Scholar